Orforglipron for obesity treatment in older patients ≥65 years with or without type 2 diabetes: A post hoc subgroup analysis of the ATTAIN-1 and ATTAIN-2 trials [0.03%]
塞利谷促胰岛素素治疗≥65岁老年人肥胖(有或没有2型糖尿病)的后hoc亚组分析(attain-1和attain-2试验)
Deborah B Horn,Alpana P Shukla,Haocheng Huang et al.
Deborah B Horn et al.
Background: Limited studies exist on incretin-based medications in older adults with obesity. Orforglipron, a novel small-molecule, non-peptide, oral glucagon-like peptide-1 receptor agonist (GLP-1 RA), led to significant...
Creation and validation of the 8-Item Brief Emotional Eating Scale (BEES-8, version 1.0) in youth and adults [0.03%]
青少年和成人情绪性饮食行为量表（简版）的编制与验证
David Javier-Aliaga,Dámaris Quinteros-Zúñiga
David Javier-Aliaga
Introduction: Although several instruments have been developed to assess emotional eating, no measure has yet been identified that evaluates this construct based on the eight basic emotions. Assessing emotional eating is ...
Familial health behavioral change in the context of adult treatment with obesity medications [0.03%]
肥胖药物成人治疗背景下的家族健康行为改变
Treah Haggerty,Jennifer M Ludrosky,Molly Powney et al.
Treah Haggerty et al.
Background: Childhood obesity is a serious public health crisis in the United States, affecting millions of children annually and is associated with significant, long-term physical and psychological consequences. Family-b...
Projected budget impact of pharmacotherapy scenarios for obesity and related conditions in Peru: A national survey analysis of 76,819 participants [0.03%]
秘鲁肥胖及相关疾病药物治疗方案的预算影响分析：一项76819名受试者全国调查研究
Victor J Vera Ponce
Victor J Vera Ponce
Background: The increasing prevalence of obesity is generating demand for chronic pharmacologic treatment, but Latin American evidence on population-level budget implications remains limited. ...
Nutritional considerations for glucagon-like peptide-based therapies: An Asian Indian consensus recommendation [0.03%]
基于GLP的治疗方案中的营养考虑因素：印度人的共识建议
Shashank R Joshi,Anoop Misra,Ambrish Mithal et al.
Shashank R Joshi et al.
Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonists, collectively called GLP-based therapies (GBTs), cause gastrointest...
Employee perceptions and experiences with tirzepatide treatment for obesity or overweight in the US: Insights from the PERCEPTIONS Survey [0.03%]
美国员工对 tirzepatide 治疗肥胖或超重的感知和体验——来自 PERCEPTIONS 调查的见解
Theresa Hunter Gibble,Tamara Al-Zubeidi,Claire Gerber et al.
Theresa Hunter Gibble et al.
Objective: To characterize real-world experiences, perceptions, and workplace-related outcomes among full-time employed adults in the United States with obesity or overweight initiating tirzepatide for obesity management,...
Belma Gözde Özdemir
Belma Gözde Özdemir
Introduction: Obesity is a major public health challenge with substantial effects on women's health and quality of life. Pelvic organ prolapse (POP), characterized by the descent of pelvic organs into the vaginal canal, i...
Resolution of anhedonia-like symptoms in patients treated for obesity with tirzepatide: A three-case series [0.03%]
tirzepatide治疗肥胖患者的快感缺失样症状改善个案报告三则
Spencer Nadolsky,Summer Kessel,Zachary A Krumm et al.
Spencer Nadolsky et al.
Introduction: Glucagon-like peptide-1 receptor agonists (GLP1RAs) have demonstrated substantial efficacy for obesity and metabolic disease treatment, with emerging evidence suggesting effects on reward-processing pathways...
Case Reports
Obesity pillars. 2026 Jul 14:19:100302. DOI:10.1016/j.obpill.2026.100302 2026
Changes in self-esteem, body dissatisfaction, and body appreciation during face-to-face and digital supervised physical activity interventions in women with obesity: A dual-study investigation [0.03%]
面向肥胖女性的面对面和数字监督身体活动干预中的自尊、身材不满和身材欣赏变化：双重研究调查
Lisa Moyon,David Le Foll,Alexandre Mazéas et al.
Lisa Moyon et al.
Background: Physical activity (PA) is a cornerstone of obesity treatment. However, changes in self-perceptions during supervised PA interventions remain insufficiently understood, particularly regarding their temporal dyn...
A survey of primary care physicians' views on supporting patients who lose insurance coverage for Glucagon-Like Peptide-1-based drugs for weight management [0.03%]
关于初级保健医师支持因胰高血糖素样肽-1类药物体重管理而失去保险覆盖的患者的意见调查
Lauren Oshman,Amy Runyon,Alexis Vicenzi Bal et al.
Lauren Oshman et al.
Background: Glucagon-like peptide-1 (GLP-1)-based drugs for weight management are commonly prescribed by primary care physicians (PCPs), many of whom have limited familiarity with alternative weight management treatments....